National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
May 2008 September 2008 Reimbursement recommended.

A summary of the main findings are included in the attached document.

Rivaroxaban (Xarelto) summary